The following are selected publications and patents resulting from Provid internal programs and client collaborations (public domain).
Olson GL, Self CR, Sun Y, inventors. Provid Pharmaceuticals Inc., assignee. Inhibitors of antigen presentation by MHC class II HLA-DRB1*15:01 molecules with enhanced metabolic stability. USA patent application US-20240158439-A1. 2024 May.
Allen JE, Olson GL, Stogniew M, Pottorf RS, Sun Y, Nallaganchu BR, inventors. Oncoceutics Inc., assignee. 7-benzyl-4-(2-methylbenzyl)-2,4,6,7,8,9-hexahydroimidazo [1,2-a]pyrido[3,4-e]pyrimidin-5(1H)-one, analogs thereof, and salts thereof and methods for their use in therapy. USA US-11976068-B2. 2024 May.
Olson GL, Sun Y, Nallaganchu BR, inventors. Supernus Inc., assignee. Process of making derivatives of substituted morpholines. USA US-11964951-B2. 2024 April.
Allen JE, Kline CLB, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Correction: Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2021 Oct 12;12(21):2231. doi: 10.18632/oncotarget.28012. eCollection 2021 Oct 12. PubMed PMID: 34676056; PubMed Central PMCID: PMC8522842.
Christianson DW, Olson GL, Tomczuk BE, Pottorf RS, Colasanti AV, inventors. Arginetix INc, assignee. Arginase Inhibitors and Methods of Use. USA patent application US-20200223871-A1. 2020 July.
Ooi and colleagues evaluated PV-267 in DR15 transgenic mice in a model of Goodpasture’s (anti-GBM) disease. The study demonstrated that HLA-DR15 inhibition attenuates the type IV collagen α3(IV)NC1antigen-specific pro-inflammatory responses supporting use of DR15 antagonists as an adjunct therapy for anti-GBM disease. The results are comparable to those observed in the MS model, demonstrating that inhibition is directed to the MHC DR15 binding site and is independent of the specific antigen.
Wagner J, Kline CL, Ralff MD, Lev A, Lulla A, Zhou L, Olson GL, Nallaganchu BR, Benes CH, Allen JE, Prabhu VV, Stogniew M, Oster W, El-Deiry WS. Preclinical evaluation of the imipridone family, analogs of clinical stage anti-cancer small molecule ONC201, reveals potent anti-cancer effects of ONC212. Cell Cycle. 2017 Oct 2;16(19):1790-1799. doi: 10.1080/15384101.2017.1325046. Epub 2017 May 10. PubMed PMID: 28489985; PubMed Central PMCID: PMC5628644.
Allen JE, Kline CL, Prabhu VV, Wagner J, Ishizawa J, Madhukar N, Lev A, Baumeister M, Zhou L, Lulla A, Stogniew M, Schalop L, Benes C, Kaufman HL, Pottorf RS, Nallaganchu BR, Olson GL, Al-Mulla F, Duvic M, Wu GS, Dicker DT, Talekar MK, Lim B, Elemento O, Oster W, Bertino J, Flaherty K, Wang ML, Borthakur G, Andreeff M, Stein M, El-Deiry WS. Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. 2016 Nov 8;7(45):74380-74392. doi: 10.18632/oncotarget.11814. Review. PubMed PMID: 27602582; PubMed Central PMCID: PMC5342060.
Wagner J, Kline CL, Pottorf RS, Nallaganchu BR, Olson GL, Dicker DT, Allen JE, El-Deiry WS. The angular structure of ONC201, a TRAIL pathway-inducing compound, determines its potent anti-cancer activity. Oncotarget. 2014 Dec 30;5(24):12728-37. doi: 10.18632/oncotarget.2890. PubMed PMID: 25587031; PubMed Central PMCID: PMC4350349.
Ji N, Somanaboeina A, Dixit A, Kawamura K, Hayward NJ, Self C, Olson GL, Forsthuber TG. Small molecule inhibitor of antigen binding and presentation by HLA-DR2b as a therapeutic strategy for the treatment of multiple sclerosis. J Immunol. 2013 Nov 15;191(10):5074-84. doi: 10.4049/jimmunol.1300407. Epub 2013 Oct 11. PubMed PMID: 24123687; PubMed Central PMCID: PMC3891844.
Ebright RH, Ebright YW, Olson GL, Hiebel A, Shen J, Bacci J, Solvibile W, Self CR, inventors. Rutgers, the State University of New Jersey and Provid Pharmaceuticals Inc., assignee. Antibacterial agents: aryl myxopyronin derivatives. USA US-9592221-B2. 2012 July.
Olson GL, Cook CM, Self CR, inventors. Provid Pharmaceuticals Inc., assignee. Methods for the use of inhibitors of antigen presentation by MHC class II molecules. USA US-8222215-B2. 2012 July.
Roth S, Buck C, Self CR, Olson GL, inventors. Immune Control Inc, assignee. Compositions for treatment of diseases related to activated lymphocytes. USA US-7981885-B2. 2011 July.
Ross S, Buck C, Self CR, Olson GL, inventors. Immune Control Inc., assignee. Compositions for treatment of diseases related to activated lymphocytes. USA US-7981885-B2. 2011 July.
Roth S, Buck C, Self CR, Olson GL, inventors. Immune Control Inc., assignee. Compositions for treatment of diseases related to activated lymphocytes. USA US-7981885-B2. 2011 July.
Olson GL, Cook CM, Self CR, inventors. Provid Pharmaceuticals Inc., assignee. Inhibitors of antigen presentation by MHC class II molecules and methods of use thereof. USA US-7439231-B2. 2008 October.
Braun A, Kammerer SM, Cantor CR, Burns-Hamuro L, Taylor S, Cook CM, Self CR, Olson GL, inventors. Sequenom, Inc., assignee. Kinase anchor protein muteins, peptides thereof and related documents. USA US-7432342-B2. 2008 October.
Burns-Hamuro LL, Ma Y, Kammerer S, Reineke U, Self C, Cook C, Olson GL, Cantor CR, Braun A, Taylor SS. Designing isoform-specific peptide disruptors of protein kinase A localization. Proc Natl Acad Sci U S A. 2003 Apr 1;100(7):4072-7. doi: 10.1073/pnas.2628038100. Epub 2003 Mar 19. PubMed PMID: 12646696; PubMed Central PMCID: PMC153050.